Repligen Corporation $RGEN Position Increased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its holdings in Repligen Corporation (NASDAQ:RGEN) by 4,247.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,000 shares of the biotechnology company’s stock after buying an additional 4,885 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Repligen were worth $668,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of RGEN. Rhenman & Partners Asset Management AB lifted its holdings in shares of Repligen by 333.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock valued at $2,425,000 after purchasing an additional 15,000 shares in the last quarter. XTX Topco Ltd raised its position in Repligen by 34.1% during the second quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after buying an additional 4,417 shares during the period. Delta Investment Management LLC purchased a new stake in Repligen in the 3rd quarter worth about $6,779,000. Congress Asset Management Co. boosted its position in Repligen by 43.4% during the 3rd quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after acquiring an additional 66,142 shares during the period. Finally, Blue Whale Capital LLP purchased a new position in Repligen during the 2nd quarter valued at about $35,782,000. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, Director Karen A. Dawes sold 275 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the transaction, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This represents a 0.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.20% of the company’s stock.

Repligen Stock Down 1.1%

Repligen stock opened at $135.68 on Friday. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $175.77. The firm’s fifty day simple moving average is $156.81 and its 200-day simple moving average is $146.10. The company has a market capitalization of $7.64 billion, a P/E ratio of 6,787.39, a P/E/G ratio of 2.50 and a beta of 1.13.

Analysts Set New Price Targets

RGEN has been the subject of a number of research analyst reports. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Wells Fargo & Company increased their target price on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Barclays lifted their target price on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Finally, Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.